Literature DB >> 12349941

PPAR and immune system--what do we know?

Xia Zhang1, Howard A Young.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear steroid receptor superfamily. Originally, the receptors were identified as critical controllers for several key enzymes that catalyze the oxidation of fatty acids. PPARs consist of three members: PPAR-alpha, PPAR-beta/delta, and PPAR-gamma. Among them, PPAR-gamma is essential for controlling thermogenesis and adipocyte differentiation. The ligands for PPAR-gamma include 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2)--a metabolite from the prostaglandin synthesis pathway, and "glitazones"--drugs utilized in the treatment of patients with diabetes. The precursors for prostaglandins are fatty acids consumed from diet and these precursors have long been postulated to have a regulatory role in immune functions. Emerging evidence indicates that PPAR-gamma and its ligands are indeed important for the modulation of immune and inflammatory reactions. In this review, we will spotlight the molecular mechanisms of receptor/ligand function and how they may regulate immune and inflammatory reactions. We also propose that PPAR-gamma and its endogenous ligands are participating factors for Type 1/Type 2 T and NK cell differentiation and development. Deciphering the mechanism of action of PPAR-gamma and its ligands may lead to a new therapeutic regiment for treatment of diseases involving dysfunction of the immune system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12349941      PMCID: PMC2543934          DOI: 10.1016/s1567-5769(02)00057-7

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  113 in total

1.  A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition.

Authors:  Fabrice Bureau; Christophe Desmet; Dorothée Mélotte; Fabrice Jaspar; Cédric Volanti; Alain Vanderplasschen; Paul-Pierre Pastoret; Jacques Piette; Pierre Lekeux
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

2.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.

Authors:  I Issemann; S Green
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

3.  Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein.

Authors:  Aaron V Pontsler; Andy St Hilaire; Gopal K Marathe; Guy A Zimmerman; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2002-01-23       Impact factor: 5.157

Review 4.  Cyclooxygenases and prostaglandins: shaping up the immune response.

Authors:  Bianca Rocca; Garret A FitzGerald
Journal:  Int Immunopharmacol       Date:  2002-04       Impact factor: 4.932

5.  The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation.

Authors:  Salvatore Cuzzocrea; Nicole S Wayman; Emanuela Mazzon; Laura Dugo; Rosanna Di Paola; Ivana Serraino; Domenico Britti; Prabal K Chatterjee; Achille P Caputi; Christoph Thiemermann
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

6.  Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation.

Authors:  C Natarajan; J J Bright
Journal:  Genes Immun       Date:  2002-04       Impact factor: 2.676

7.  The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands.

Authors:  Barry Marc Forman
Journal:  J Biol Chem       Date:  2002-02-27       Impact factor: 5.157

8.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

Authors:  J M Lehmann; L B Moore; T A Smith-Oliver; W O Wilkison; T M Willson; S A Kliewer
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

9.  Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition.

Authors:  S Narumiya; M Fukushima
Journal:  J Pharmacol Exp Ther       Date:  1986-11       Impact factor: 4.030

10.  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.

Authors:  M E Greene; B Blumberg; O W McBride; H F Yi; K Kronquist; K Kwan; L Hsieh; G Greene; S D Nimer
Journal:  Gene Expr       Date:  1995
View more
  28 in total

1.  Differentially expressed genes in PPARγ-deficient MSCs.

Authors:  Yun Su; Xiaona Shen; Jie Chen; Carlos M Isales; Jing Zhao; Xing-Ming Shi
Journal:  Mol Cell Endocrinol       Date:  2017-07-31       Impact factor: 4.102

2.  Differential expression of AdipoR1, IGFBP3, PPARγ and correlative genes during porcine preadipocyte differentiation.

Authors:  Hai-Feng Liu; Ming-Xing Gui; Han Dong; Xun Wang; Xue-Wei Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-12-15       Impact factor: 2.416

Review 3.  Significance of anti-inflammatory effects of PPARgamma agonists?

Authors:  G Rogler
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

4.  Nutrition, anabolism, and the wound healing process: an overview.

Authors:  Robert H Demling
Journal:  Eplasty       Date:  2009-02-03

5.  Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARδ in inflammation-induced colon carcinogenesis.

Authors:  Jennifer M Monk; Wooki Kim; Evelyn Callaway; Harmony F Turk; Jennifer E Foreman; Jeffrey M Peters; Weimin He; Brad Weeks; Robert C Alaniz; David N McMurray; Robert S Chapkin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-22       Impact factor: 4.052

6.  Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.

Authors:  Morgan T Sutton; David Fletcher; Nicole Episalla; Lauren Auster; Sukhmani Kaur; Mary Chandler Gwin; Michael Folz; Dante Velasquez; Varun Roy; Rolf van Heeckeren; Donald P Lennon; Arnold I Caplan; Tracey L Bonfield
Journal:  J Stem Cell Res Ther       Date:  2017-09-22

Review 7.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

8.  Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin.

Authors:  Mei Li; Nadia Messaddeq; Marius Teletin; Jean-Louis Pasquali; Daniel Metzger; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

9.  Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.

Authors:  David J van Westerloo; Sandrine Florquin; Anita M de Boer; Joost Daalhuisen; Alex F de Vos; Marco J Bruno; Tom van der Poll
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages.

Authors:  E-L Paukkeri; T Leppänen; O Sareila; K Vuolteenaho; H Kankaanranta; E Moilanen
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.